1. India Stocks

  2. •

    Distribution services

  3. •

    Wholesale distributors
Saroja Pharma Industries India Ltd.

Saroja Pharma Industries India Ltd.

NNSE:SAROJA
40.80
INR
0.00
(0.00%)
4.02EPS
6.97P/E
112.57MMarket Cap
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
91.19
138.37
124.84
115.21
133.63
174.43
Basic EPS, GAAP
1.82
2.84
2.64
2.49
2.57
4.02
Free Cash Flow per Basic Share
-2.74
-9.91
-6.32
-10.49
-3.6
-10.65
Dividend per Share
- -
- -
- -
- -
- -
- -
Book Value per Share
2.33
10.01
12.65
36.42
38.99
43.01
Tangible Book Value per Share
2.32
10.01
12.65
36.42
38.99
43.01
Basic Weighted Avg Shares
4
4
4
4
4
4
Sales/Revenue/Turnover
367
556
502
407
537
701
Operating Margin (%)
3.5
3.7
5.29
6.06
4.98
5.28
Depreciation Expense
- -
- -
1
1
1
1
Net Income, GAAP
7
11
11
9
10
16
Effective Tax Rate (%)
28.5
27.61
28.89
27.24
28.64
27.7
Profit Margin (%)
1.99
2.05
2.11
2.16
1.92
2.3
Working Capital
22
53
27
83
47
15
LT Debt
14
17
28
26
14
74
Total Equity
9
40
51
146
157
173
Return on Invested Capital (%)
- -
20.98
14.73
9.99
8.36
9.14
Return on Capital (%)
- -
22.98
13.9
10.15
8.36
8.86
Return on Common Equity (%)
- -
45.95
23.28
8.9
6.82
9.79

Capital Structure

INR

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

INR

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
112.34%
10.3%
Free Cash Flow
- -
81.32%
196.2%
Net Income, GAAP
- -
21.12%
56.1%
Sales/Revenue/Turnover
- -
17.13%
30.53%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
407
2025
- -
- -
537
2026
- -
- -
701

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2.49
2025
- -
- -
2.57
2026
- -
- -
4.02

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Biju Gopinathan Nair
Full Time Employees
13
Sector
Distribution services
Industry
Wholesale distributors
Address
Ecstasy Buisness Park Mumbai India 400080
IPO Date
Sep 13, 2023
Website
sarojapharma.com
Similar Companies
Adani Enterprises Limited (NSE:ADANIENT)
Aegis Logistics Limited (NSE:AEGISLOG)
Marine Electricals (India) Limited (NSE:MARINE)
Mitsubishi Corporation (TSE:8058)
Fastenal Company (NASDAQ:FAST)
GigaCloud Technology Inc (NASDAQ:GCT)
Business
Saroja Pharma Industries India Ltd. (SAROJA.NS) manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for domestic and international markets. The company produces a range of generic drugs, including tablets, capsules, injectables, and ointments across therapeutic segments such as anti-infectives, cardiovasculars, gastroenterology, and analgesics; it also offers contract manufacturing services and exports to regulated markets in Africa, Southeast Asia, and Latin America. Founded in 1992 and headquartered in Hyderabad, India, Saroja operates primarily in the Indian pharmaceutical sector with manufacturing facilities compliant with WHO-GMP standards. In recent developments, the company completed a successful initial public offering (IPO) in late 2024, raising funds to expand production capacity and enter new export markets. Saroja announced a strategic partnership with a leading European distributor in early 2025 to boost its presence in the EU generics market and launched a new line of oncology injectables targeting emerging markets. Additionally, it acquired a small API intermediates facility in Gujarat in mid-2025 to vertically integrate its supply chain and reduce dependency on external suppliers.